myo-inositol for PCOS
A guideline-informing systematic review and meta-analysis plus independent studies indicate myo-inositol improves metabolic measures, menstrual regularity, and insulin resistance in PCOS patients.
Hypothesized mechanism
Myo-inositol may act as an insulin-sensitizing agent, improving insulin resistance and associated endocrine/metabolic parameters in PCOS.
This is the model’s proposed mechanism from the sources on file, not a demonstrated causal pathway. How well the published record supports it is reflected in the rigor and plausibility dimensions of the score, and traced to the verbatim sources at the foot of the page.
How the score was reached, for this pair
The composite score is the sum of five dimensions, each scored 0 to 2 by the model from the evidence on file. Below is the sub-score this specific pair received on each, with what that dimension measures. It scored 9 of 10 overall, a strong reading, from a direct rated strong in strength.
The model’s overall reasoning for this pair is the summary at the top of the page, and the mechanism it proposed is in the section above.
Scored for women. Evidence generated in women (female population, ~100% female). (band F1, ×1.00).
Corroboration
Evidence comes from multiple independent sources, including a systematic review and meta-analysis informing the 2023 PCOS guidelines (claim 1), plus separate primary studies in teenagers (claims 2-5) and overweight patients (claims 6-10). The consistency across a synthesis and independent trials supports a high corroboration score.
Rigor
Claim 1 is from a systematic review and meta-analysis, the highest tier of evidence here. The other sources are comparative treatment studies, and the meta-analysis anchors strong rigor.
Specificity
Multiple claims name both myo-inositol and PCOS directly (e.g., 'Inositol for Polycystic Ovary Syndrome' and 'treatment of patients with PCOS'). Both intervention and condition are explicitly identified.
Plausibility
The claims report improvements in insulin resistance and metabolic parameters (claims 9, 10), implying an insulin-sensitizing mechanism, but no explicit mechanistic pathway is described. The effect is plausible but only asserted, not mechanistically evidenced.
Consistency
Results consistently point in a positive direction across sources: metabolic improvements in the meta-analysis (claim 1), weight/BMI reductions in teenagers (claims 2-3), and menstrual, endocrine, and insulin-resistance improvements in patients (claims 7-10). No contradictory findings appear.
Scored for women. Female representation not stated — applicability to women uncertain (flagged for full text). (band F4, ×0.75).
Corroboration
Independence (patient accounts): 0 distinct account(s) across 1 thread(s) (author handles unavailable — counting distinct posts).
Rigor
The claim is entirely vague ('makes me more beautiful') with no dose, timing, or specific symptom described. There is no detail linking myo-inositol to any measurable PCOS outcome.
Specificity
Although myo-inositol is named, the outcome ('more beautiful') is not a clear PCOS-related endpoint and is not concretely linked to any condition symptom. The drug-outcome link is undefined.
Plausibility
Myo-inositol is plausibly associated with improved skin/hair (e.g., via reduced hyperandrogenism) in PCOS, which could loosely underlie a subjective 'more beautiful' feeling. However, the claim is too vague to firmly support any specific mechanism.
Consistency
With only one account and no dose or timing information, there is nothing to assess for internal agreement or coherence. No corroborating or conflicting reports exist.
Regulatory & development status
Where this candidate sits in the US regulatory landscape: whether the drug is already FDA-approved for pcos (on-label) or approved for something else (off-label), whether the molecule is available as a generic or a single-source brand still under patent, and how far it has been studied as a therapy for this condition. Each fact is drawn from a public US source and reported beside the score; none of it is folded into the score.
This is descriptive context, not regulatory advice. It maps the landscape a 505(b)(2)route would build on (an already-approved active ingredient proposed for a new indication), but it is not a 505(b)(2) viability assessment, and says nothing about whether any particular development path is advisable. “Approved” means FDA-approved (US); approvals elsewhere are out of scope.
Approval relationship No FDA-approved label
Read from the drug’s FDA label via DailyMed, the US National Library of Medicine’s label repository. A label is only counted when it carries an FDA-approved marketing category (an NDA, ANDA, or biologic BLA); dietary supplements, homeopathics, and OTC-monograph products are not FDA-approved drugs and are excluded.
For this pair. No FDA-approved drug label was found for this molecule (it may be a supplement, a biologic, investigational, or approved only outside the US), so any use here is investigational.
Generic & patent supply Not in the Orange Book
Read from the FDA Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations), using single-ingredient products only so that patents on novel branded combination formulations are never attributed to the base molecule.
For this molecule. Absent from the Orange Book. Biologics (listed in the Purple Book instead), dietary supplements, and drugs not FDA-approved in the US do not appear here.
Clinical-trial stage, for this condition Phase 3
Read from ClinicalTrials.gov (US National Library of Medicine). A trial only counts when the drug appears as an experimental or active-comparator intervention in an interventional study of this condition; mechanistic, drug-interaction, post-marketing (Phase 4), and comparator-background uses are excluded, so this reflects the drug being tested as a therapy for pcos.
For this pair. Studied in 24 qualifying interventional trials · highest stage reached Phase 3 · active trial(s).
Layers not covered for this pair
Not covered for this pair. This layer holds documented sex-specific pharmacokinetics for a limited set of drugs, and this compound is not among them yet. A blank here means the drug is not covered by the layer, not that no sex difference exists.
More on the sex-specific pharmacokinetics layer and its sources →Not covered for this pair. The cycle-phase layer is seeded for the strongest-evidence cases so far (PMDD), and this pair is not among them yet. A blank here means the pair is not covered by the layer, not that the effect was found to be phase-independent.
More on the cycle-phase layer and its sources →Source evidence · what the pipeline ingested
These are the sources the pipeline ingested to detect and score this signal, the published literature the model actually read, each tagged by study type. Where the model combined findings the claim is marked as a synthesis (S), and where the literature disagrees the contradiction is shown (!).
Every source below belongs to this signal’s evidence arm, Direct research. Whel reads each drug-condition pair through four such arms, each held to its own inclusion bar; a signal is surfaced through one of them.
- 1benefits for myo-inositol or D-chiro-inositol (DCI) for some metabolic measures PubMed · PMID 38163998 ↗
- 2We pointed out that the group of 13-16 years old lean teenagers treated with myo-Ins exhibit a significant decrease of weight and body mass index (BMI), and an effective improvement the metabolic and hormonal parameters achieved with a non-pharmacological treatment. PubMed · PMID 34919250 ↗
- 3group of 13-16 years old lean teenagers treated with myo-Ins exhibit a significant decrease of weight and body mass index (BMI) PubMed · PMID 34919250 ↗
- 4RESULTS: We pointed out that the group of 13-16 years old lean teenagers treated with myo-Ins exhibit a significant decrease of weight and body mass index (BMI), and an effective improvement the metabolic and hormonal parameters achieved with a non-pharmacological treatment. PubMed · PMID 34919250 ↗
These are the verbatim sources the pipeline surfaced and read; they may not be the full published record for a pair, and the score reflects the strength and agreement of the evidence rather than its volume. The strength of these source types is what the rigor dimension of the score reads off. MATRIX, sex-specific pharmacokinetics, and cycle phase are separate layers the pipeline does not ingest, external cross-references reported beside the score, and they link to their own sources in their sections above.
The primary sources and pipelines this evidence is drawn from →